DocMorris AG

DocMorris successfully completes the placement of CHF 200 million Convertible Bonds due 2029

DocMorris launches approx. CHF 200 million Convertible Bonds due 2029

DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market

DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card

DocMorris AG: Significant earnings improvement in 2023; e-prescription is standard in Germany

DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base

DocMorris optimises organisational structure and prepares for e-prescription growth in Germany

DocMorris strengthens path to profitable growth in third quarter; slightly reduced revenue outlook

DocMorris: Solid basis for sustainable, profitable growth

DocMorris AG: DocMorris demands fully digital non-discriminatory access to e-prescriptions

DocMorris announces results of tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024

DocMorris (formerly Zur Rose Group) announces a tender offer for any-and-all of its CHF 200 million outstanding bonds due 2024

New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)

Annual General Meeting 2023: Zur Rose Group AG to be renamed DocMorris AG (stock exchange ticker symbol DOCM)

Zur Rose Group has successfully completed the sale of its Swiss business to Migros

Zur Rose Group: Revenue in the first quarter 2023 in line with plan

Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023

Zur Rose Group: Revenue and earnings targets for 2022 achieved; significant step towards profitability

Zur Rose Group hands over successful Swiss business to Migros to focus on growth in Germany

Zur Rose Group: Revenue target 2022 achieved, EBITDA better than expected

Zur Rose Group takes next step towards profitability and further reduces complexity in Germany

Procurement and supply chain brought together under the new Chief Operations Officer

Zur Rose Group announces results of Tender Offer

After the first nine months, the Zur Rose Group is at the upper end of targets for revenue and EBITDA for 2022

Zur Rose Group announces preliminary result and extension of Tender Offer

Zur Rose Group announces a tender offer for all of its CHF 115 million outstanding bonds due 2023

Final allocations of Zur Rose approx. CHF 95 million Convertible Bonds Offering

Zur Rose Group successfully completes placement of approx. CHF 95 million Convertible Bonds and the approx. CHF 44 million Capital Increase by way of an accelerated book building process

Zur Rose Group launches approx. CHF 100 million Convertible Bonds and approx. CHF 50 million Capital Increase by way of an accelerated book building process

Zur Rose Group speeds up path to profitability and plans break-even at EBITDA level in 2023